AI Governance Market in Healthcare to Hit $19.65B by 2035

The AI in Healthcare Governance and Safety market is projected to reach $19.65 billion by 2035, reflecting both rapid AI adoption in clinical settings and intensifying regulatory demands for safe, ethical deployment MarketWatch. Enterprise health systems and vendors face mounting pressure to implement robust governance frameworks to manage risk and ensure compliance.

The global AI in Healthcare Governance and Safety market is forecasted to grow from $3.7 billion in 2024 to $19.65 billion by 2035, according to a new industry report released June 10, 2024 MarketWatch. This surge is driven by the expanding use of AI in diagnostics, treatment planning, and patient management, alongside a wave of new regulations and standards targeting AI safety and ethical risk management in healthcare. The report highlights that both healthcare providers and technology vendors are significantly increasing investments in governance solutions to address risks such as algorithmic bias, data privacy, and lack of transparency Healthcare IT News.

This market trajectory has direct implications for regulated healthcare enterprises. Regulatory bodies in the US, EU, and Asia-Pacific are intensifying scrutiny of AI systems used in clinical decision-making, with frameworks such as the EU AI Act, FDA’s Good Machine Learning Practice (GMLP), and HIPAA privacy rules mandating demonstrable governance and risk management European Commission. The NIST AI Risk Management Framework (RMF) is also emerging as a de facto standard for operationalizing trustworthy AI in healthcare. As AI becomes integral to patient care, failure to comply with these frameworks exposes organizations to regulatory penalties, reputational harm, and patient safety incidents.

For CTOs, CISOs, and Compliance Officers, the next 30-90 days are critical for evaluating current AI governance maturity and identifying gaps relative to new and pending regulations. Immediate action items include mapping AI use cases against regulatory requirements, assessing third-party vendor compliance, and prioritizing investments in explainability, bias mitigation, and auditability tools. Organizations should also monitor evolving guidance from the FDA, HHS, and international regulators, as enforcement actions and new standards are expected to accelerate in the coming year Healthcare IT News.

What This Means for Enterprise AI

Healthcare enterprises must operationalize comprehensive AI governance programs that address both technical and organizational risks. The EU AI Act, for example, classifies most clinical AI as “high-risk,” requiring documented risk assessments, human oversight, and continuous monitoring throughout the AI lifecycle European Commission. In the US, the FDA’s GMLP and HIPAA rules demand robust data governance, traceability, and incident response protocols for AI-enabled systems.

CTOs should prioritize integrating AI governance platforms capable of real-time monitoring for bias, drift, and security vulnerabilities. CISOs must ensure that AI models handling protected health information (PHI) comply with HIPAA and are subject to regular privacy impact assessments. Compliance Officers should establish cross-functional governance committees to oversee AI risk, update policies in line with NIST AI RMF, and prepare for external audits.

Failure to act exposes organizations to regulatory fines, loss of payer contracts, and patient harm. Early adopters of robust AI governance will be better positioned to scale AI safely, win trust, and maintain compliance as the regulatory environment tightens.